Teva: European Commission Grants Marketing Authorizations For Biosimilars PONLIMSI, DEGEVMA

(RTTNews) - Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries (TEVA), announced that the European Commission has granted marketing authorizations for its two denosumab biosimilar candidates PONLIMSI, a biosimilar to Prolia and DEGEVMA, a biosimilar to Xgeva. Teva plans to launch both products in key European markets in the coming months.

Steffen Nock, SVP Head of Biosimilars & Chief Science Officer, said: "This approval represents an important step forward in increasing patient access to biosimilar therapies for serious bone conditions."

For More Such Health News, visit rttnews.com.